Event Participants
Executives
8 Shri. Ramesh Babu Potluri (Chairman & Managing Director), Shri. Vamsi Krishna Potluri (Executive Director), Shri. Shravan Kudravallii (Independent Director), Shri. Sarvepalli Srinivas (Director), Shri. Dr. Suresh Kumar Gangavarapu (Independent Director), Shri. Sunkara Venkata Satya Shiva Prasad (Non-Executive Non Independent Director), Smt. Shanti Sree Bolleni (Independent Director), Shri. Trilok Potluri (Non-Executive Non Independent Director)
Analysts
0 Transcript incomplete - Q&A section not available for summary. This is an investor presentation deck without analyst interaction.
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹206.96 crores | +6% YoY, -13% QoQ; driven by diversified growth across high-value APIs |
| Gross Profit | ₹74.93 crores | +12% YoY, -8% QoQ; gross margin (ex. mfg expenses) at 46% vs 44% YoY |
| Gross Margin (ex. mfg expenses) | 46% | +200bps YoY; structural improvement from high-value mix and process optimisation |
| Gross Margin (reported) | 36% | +217bps YoY, +204bps QoQ; reflects better realisation per MT |
| EBITDA | ₹40.95 crores | +4% YoY, +3% QoQ; margin sustained at ~20% despite revenue dip QoQ |
| EBITDA Margin | 20% | -30bps YoY, +302bps QoQ; operating leverage from scalable manufacturing |
| PAT (ex. associate) | ₹20.20 crores | +8% YoY, -4% QoQ; PAT margin at 10% (+21bps YoY, +95bps QoQ) |
| PAT (incl. associate) | ₹20.91 crores | +2% YoY, -36% QoQ; associate contribution dropped to ₹0.71cr from ₹11.75cr QoQ |
| EPS | ₹2.23 | -3% YoY, -38% QoQ; FY26 EPS at ₹11.15 (+37% YoY) |
| R&D Team Strength | 200 scientists | Increased from 100+; supports niche API and peptide pipeline development |
| DMF/CEP Filings (Q1) | 4 | On track for FY27 target of 10 filings; 120+ cumulative filings to date |
| Capex Programme | ₹280 crores | 89% brownfield, 11% greenfield; completion targeted by FY27; high-teens return profile |
| Net Asset Turnover | 1.36x | Targeting 1.75x over next 2-3 years via volume ramp and asset utilisation |
| Revenue from Regulated Markets | 88% | FY26 share; 75+ countries presence; Europe 31%, Asia ex-India 26%, NA 15% |
| High-Value Product Share | 51% | FY26 revenue share; up from 40% in FY21; drives margin durability |
| OCF/EBITDA Conversion | 66% | 10-year average; on par with leading API peers |
Geographic & Segment Commentary
Europe (31% of FY26 revenue): Largest geography; sustained demand for anti-inflammatory and ARV portfolios; benefits from established customer relationships with large pharma majors.
Asia ex-India (26% of FY26 revenue): Second-largest market; includes EOU/SEZ/DE sales (22%); serves as key export corridor for high-volume APIs.
North America (15% of FY26 revenue): Regulated market presence reinforced by 6 USFDA approvals at Hyderabad and 4 at Vizag; anti-migraine and anti-diabetic portfolios drive high-value growth.
India (6% of FY26 revenue): Domestic leadership in key products; supports volume base for anti-inflammatory and anti-ulcer segments.
Anti-inflammatory (20% of FY26 revenue, High-volume): 138% CAGR FY21-26; targeting global #1 position; backward integration and Chemo partnership driving scale.
ARV (28% of FY26 revenue, High-volume): Largest therapeutic area; stable regulated market demand; contributes significantly to volume-led revenue base.
Anti-diabetic (15% of FY26 revenue, High-value): Key high-value driver; lab-scale development and commercial validation completed for new pipeline molecules.
Anti-migraine (11% of FY26 revenue, High-value): Established leadership position; USFDA-approved facilities support regulated market penetration.
**Other High-value APIs (Anti-erectile dysfunction 6%, Anti-epileptic 6